SCHEMBL22358261

SCHEMBL22358261

CC(C)n1ncc2ccc(-c3noc(N4CCN(C(=O)c5ccccc5)CC4)n3)cc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 1/20 0.43
MGLL Q99685 4/20 0.43
MAPT P10636 8/20 0.42
LMNA P02545 5/20 0.42
TP53 P04637 4/20 0.42
FAAH O00519 1/20 0.42
HTT P42858 2/20 0.41
NPC1 O15118 1/20 0.41
THRB P10828 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
FASN P49327 1/20 0.41
HDAC8 Q9BY41 1/20 0.40
CKS1B P61024 1/20 0.39
SKP1 P63208 1/20 0.39
SKP2 Q13309 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22358256 0.91 MAPT (0.46) MGLLMAPTLMNATP53HTT
SCHEMBL20116366 0.90 GRM5 (0.44) MAPTTP53HTTALDH1A1SMN1; SMN2
SCHEMBL22357995 0.89 MAPT (0.42) MAPTLMNATP53HTTNPC1
SCHEMBL20116454 0.86 S1PR1 (0.43) HDAC4MGLLALDH1A1FASNHDAC8
SCHEMBL22358259 0.86 MAPT (0.51) MAPTLMNATP53HTTNPC1
SCHEMBL20117123 0.84 MAPT (0.61) MAPTLMNATP53HTTNPC1
SCHEMBL22357905 0.84 MAPT (0.42) MAPTLMNATP53FAAHHTT
SCHEMBL22357882 0.84 SMN1; SMN2 (0.54) MGLLLMNAHTTALDH1A1SMN1; SMN2
SCHEMBL22357990 0.84 MAPT (0.46) HDAC4MAPTLMNATP53HTT
SCHEMBL20116404 0.84 MAPT (0.46) MAPTLMNATP53HTTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 HDAC4 496/4885MGLL 3982/4885MAPT 22/4885
US-20200262828-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 HDAC4 496/4885MGLL 3982/4885MAPT 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.